Navigation Links
CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Date:4/26/2012

which include revenues of approximately $500,000 related to the use of funds received from the U.S. Department of Defense in connection with the development of BioFoam.  This represents annual total revenue growth of 5 percent to 8 percent.  The Company expects tissue processing revenues to be flat for the full year of 2012 compared to 2011.  Revenues from the Company's higher margin product segment are expected to grow between 10 percent and 15 percent for the full year of 2012.  This includes expectations for BioGlue and BioFoam revenues to increase in the low to mid-single digits on a percentage basis in 2012 compared to 2011, and PerClot revenues to be between $3.5 million and $4.5 million.  The Company expects revenues from revascularization technologies to be between $10.5 million and $11.5 million in 2012.  Research and development expenses are expected to be between $10.0 million and $12.0 million in 2012 as a result of the Company's investments in its U.S. clinical trials for Perclot and BioFoam, along with its European pilot study for TMR with biologics.  The Company expects earnings per share of between $0.14 and $0.18 in 2012, which includes the increased research and development expenses described above, along with increased legal expenses related to the Company's ongoing litigation with Medafor.  The Company's earnings per share guidance excludes expenses related to business development and potential share repurchases, which cannot currently be estimated.  The Company has estimated litigation expense conservatively on the high end of the anticipated range of between $5.0 million and $6.0 million, because litigation expenses are extremely variable and are not easily predicted.

The Company expects the effective income tax rate for 2012 to be in the mid thirty percent range. 

The Company's financial guidance for the full year of fiscal 2012 is subject to the risks described below in the last
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
2. CryoLife Enhances Management Team with Promotions
3. CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
4. CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
5. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
7. CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
8. CryoLife Provides Update on ValveXchange®, Inc. Investment
9. CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
10. CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
11. CryoLife Makes Equity Investment in ValveXchange® Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , and DURHAM, N.C. , July ... today announced its acquisition of assets related to the ... PFE ) that had previously been obtained as part ... also acquired all of Pfizer,s rights to the "Icagen" ... brand and will provide comprehensive services for ion channel ...
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... 2, 2015  The Commission for Certification in ... an organization that represents pharmacists in acute and ... continuing education for recertification of Certified Geriatric Pharmacists.  ... programs for this purpose.  ASHP will join the ... for the CCGP Professional Development Program. ...
Breaking Medicine Technology:Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... Food and Drug Administration for its Abbreviated New ... Powder for Solution. Perrigo is expecting to begin ... under store brand labels and is comparable to ...
... BATESVILLE, Ind., Oct. 6 Hill-Rom Holdings, Inc. (NYSE: ... has unanimously approved enhancements to the Company,s corporate ... of majority voting in uncontested elections. The ... for a majority voting standard for the election of directors ...
Cached Medicine Technology:Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350 2Hill-Rom Announces Corporate Governance Enhancements 2Hill-Rom Announces Corporate Governance Enhancements 3Hill-Rom Announces Corporate Governance Enhancements 4
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the only ... lead a national president recruitment for Regional Care, Inc. in Scottsbluff, ... E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County ... 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William ... practical points of investigating these types of cases. , Each year, New York ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the largest ... MD as the new Medical Director of its Frisco facility. , “We are pleased ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/3/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... biblical truth and expose popular lies regarding proper relationships according to the bible. ... goes into the core of the subject by explaining why certain types of sexual ...
Breaking Medicine News(10 mins):Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... evidence of the H1N1 virus in animals in Africa. In one ... studied had been exposed to the H1N1 virus, commonly known as ... every pig in this village was exposed," said Thomas B. Smith, ... of the research. "Africa is ground zero for a new pandemic. ...
... , FRIDAY, Sept. 23 (HealthDay News) -- Fred Wyand has ... the public health response to human papillomavirus, or HPV. ... News , a bimonthly newsletter published by the American Social ... HPV is a sexually transmitted disease that most people ...
... -- There is a genetic link between schizophrenia and ... a new study indicates. Researchers identified 11 genetic ... which play a role in people,s risk for these ... into the causes of both conditions. "Schizophrenia and ...
... brain doesn,t stop developing at adolescence, but continues well into ... & Dentistry at the University of Alberta. It ... human brain stopped developing in adolescence. But now there is ... to medical research conducted in the Department of Biomedical Engineering ...
... CHICAGO --- A drug used to treat cancer may also ... organs or skin, such as pulmonary fibrosis or scleroderma. ... of fibrotic proteins in human cells and the development of ... to a new Northwestern Medicine study published in the journal ...
... , THURSDAY, Sept. 22 (HealthDay News) -- People with type ... an increased risk of developing pancreatitis and pancreatic cancer, a ... (exenatide) may raise the risk of thyroid cancer. Although ... noted. "We have raised concern that there may be ...
Cached Medicine News:Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 2Health News:UCLA scientists find H1N1 flu virus prevalent in animals in Africa 3Health News:Stress the 'Human' in HPV, One Man Suggests 2Health News:Stress the 'Human' in HPV, One Man Suggests 3Health News:Genetic Links Seen Between Bipolar Illness and Schizophrenia 2Health News:Some brain wiring continues to develop well into our 20s: U of A study 2Health News:Cancer drug may also work for scleroderma 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 2Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 3Health News:Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests 4
... Streck-Kleen is an enzymatic cleanser for ... Coulter® Counters. The 475ml bottle has a ... MD Series instruments that require manual addition ... is a feature of this product. The ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... balanced electrolyte solution manufactured for use as ... sizing. Streck-Diluent III is for use on ... JS, JT, S-Plus IV, V, VI with ... 1400 and 1600. The shelf life is ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
Medicine Products: